For UK MedTech companies
Clinicians who use your device rarely tell their colleagues about it
In healthcare, peer recommendation carries more weight than any sales call. Yet most MedTech companies leave early adopters without the evidence, prompts, or support needed to become active advocates.
Two minutes. Solva follows up with specific peer advocacy programme options.
- Slow or stagnant growth in new clinic adoption despite initial positive feedback from early users
- Sales teams consistently encountering skepticism from clinicians who require peer validation before committing
- Lack of readily available, UK-specific case studies or data to support product claims during clinical discussions
- High reliance on direct sales efforts rather than organic clinical advocacy for market penetration
- Increased sales cycle length due to prolonged clinician evaluation and decision-making processes
- Higher customer acquisition costs as direct marketing and sales efforts need to compensate for lack of organic referrals
- Reduced market share and slower revenue growth, directly impacting profitability
- Increased marketing and sales expenditure to overcome resistance and build trust, impacting profit margins
- Perception of the MedTech solution as unproven or lacking widespread clinical acceptance
- Difficulty attracting top clinical talent for future collaborations or advisory boards
86% of MedTech SMEs plan to generate Real World Evidence (RWE) for their products, highlighting its importance for clinical acceptance. (CPI Group, 2025)
Source: https://www.uk-cpi.com/challenges-and-opportunities-for-the-uk-medtech-sme-ecosystem-2025
Frequently asked questions
Why does this problem persist?
Peer-to-peer recommendations are crucial in healthcare, driven by trust, proven efficacy, and positive clinical experience. MedTech companies often fail to adequately support early adopters in championing their products, or lack the robust real-world evidence needed to convince other clinicians of their solution's value and superiority.
What is the cost of leaving it unaddressed?
No verified UK data available
This is exactly what I do with UK private practices. Answer the few questions above and I'll come back personally with where to start. Paul.